Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 11/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | BPTF | Q12830 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30656691 | 1.00 | NOTUM (0.46) | NOTUMCHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL22655589 | 1.00 | NOTUM (0.46) | NOTUMCHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL22655484 | 1.00 | NOTUM (0.46) | NOTUMCHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL30656676 | 1.00 | NOTUM (0.46) | NOTUMCHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL22680292 | 0.89 | NOTUM (0.47) | NOTUMCHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL22655612 | 0.89 | NOTUM (0.47) | NOTUMCHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL22655513 | 0.89 | FFAR4 (0.51) | NOTUMCHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL22680294 | 0.89 | FFAR4 (0.51) | NOTUMCHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL22655565 | 0.89 | NOTUM (0.47) | NOTUMCHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL22655614 | 0.89 | FFAR4 (0.51) | NOTUMCHRM2CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339165-B2 | Pyrazolopyrimidines having activity against the respiratory syncytial virus (RSV) | Janssen Sciences Ireland Unlimited Company (IE) | 2022-05-24 | — | — | US | disclosed |
| US-20200361942-A1 | PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST THE RESPIRATORY SYNCYTIAL VIRUS (RSV) | Janssen Sciences Ireland Unlimited Company (IE) | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361942-A1 | PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST THE RESPIRATORY SYNCYTIAL VIRUS (RSV) | RRP15, MAVS, ACE | NOTUM 4050/4885CHRM2 4411/4885CHRM5 3405/4885 |
| US-11339165-B2 | Pyrazolopyrimidines having activity against the respiratory syncytial virus (RSV) | RRP15, MAVS, ACE | NOTUM 4050/4885CHRM2 4411/4885CHRM5 3405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.